---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Epidemiology and eligible population inputs"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Epidemiology and eligible population inputs. Topics: Estimated new cases and deaths in the United States in 2026 by head and neck site, Oral cavity and pharynx cancer incidence in the United States, Laryngeal cancer incidence in the United States, Stage at diagnosis of oral cavity and pharynx cancer, and 9 further topics. 13 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics/epidemiology-and-eligible-population-inputs"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Epidemiology and eligible population inputs

<a id="heading-4.2.3"></a>

## 4.2.3 Epidemiology and Eligible Population Inputs

<a id="topic-4.2.3-1"></a>

### Budget impact model of ficerafusp alfa: eligible population inputs

No evidence found.

<a id="topic-4.2.3-2"></a>

### Estimated new cases and deaths in the United States in 2026 by head and neck site

| Site | Estimated new cases, both sexes | Estimated deaths, both sexes |
| --- | --- | --- |
| Oral cavity and pharynx | “60,480” | “13,150” |
| Tongue | “20,420” | “3,560” |
| Mouth | “15,810” | “3,340” |
| Pharynx | “21,760” | “4,760” |
| Other oral cavity | “2,490” | “1,490” |
| Larynx | “12,290” | “3,960” |

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-4.2.3-3"></a>

### Oral cavity and pharynx cancer incidence in the United States

> “In 2026, it is estimated that there will be 60,480 new cases of oral cavity and pharynx cancer and an estimated 13,150 people will die of this disease.”
> “The rate of new cases of oral cavity and pharynx cancer was 11.7 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

<a id="topic-4.2.3-4"></a>

### Laryngeal cancer incidence in the United States

> “In 2026, it is estimated that there will be 12,290 new cases of laryngeal cancer and an estimated 3,960 people will die of this disease.”

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-4.2.3-5"></a>

### Stage at diagnosis of oral cavity and pharynx cancer

| Stage at diagnosis | Percent of cases |
| --- | --- |
| Localized (confined to primary site) | “26%” |
| Regional (spread to regional lymph nodes) | “55%” |
| Distant (cancer has metastasized) | “12%” |
| Unknown (unstaged) | “6%” |

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

<a id="topic-4.2.3-6"></a>

### Stage at diagnosis of laryngeal cancer

| Stage at diagnosis | Percent of cases |
| --- | --- |
| Localized (confined to primary site) | “49%” |
| Regional (spread to regional lymph nodes) | “30%” |
| Distant (cancer has metastasized) | “15%” |
| Unknown (unstaged) | “6%” |

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-4.2.3-7"></a>

### Share of head and neck cancer of squamous cell origin and share presenting with or progressing to recurrent or metastatic disease

> “Head and neck cancer accounts for approximately 4% of all cancers in the U.S. with over 90% of cases presenting with squamous cell origin.”
> “At the time of diagnosis, an estimated 10% of patients have metastatic disease, and up to 30% of additional patients develop a recurrence or metastases over time after initial treatment for advanced HNSCC.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-4.2.3-8"></a>

### Recurrence among older patients with locoregionally advanced disease in SEER-Medicare

> “In the resected group (n = 502), 333 patients experienced recurrence and had a 63% increased risk of death vs nonrecurrent patients”
> “In those unresected (n = 1,217), 791 patients experienced recurrence and had a 77% increased risk of death”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-4.2.3-9"></a>

### Share of recurrent or metastatic disease that is HPV-negative

> “An estimated 80% of cases of R/M HNSCC are HPV-negative, with testing for HPV status typically only being conducted in tumors originating from the oropharynx.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “In this cohort, 60.4% of patients had non-HPV associated disease, 32.6% had HPV-associated disease, and 7.0% had unknown HPV status or primary tumor site.”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12099209/)

<a id="topic-4.2.3-10"></a>

### Share of oropharyngeal squamous cell carcinoma attributable to HPV in the United States

| Measure, oropharynx, 2012 to 2016 | Value |
| --- | --- |
| Reported HPV-associated cancers, average annual number | “19,000” |
| Attributable to 9vHPV-targeted types, number (%) | “12,600 (66)” |
| Attributable to other HPV types, number (%) | “900 (5)” |
| HPV-negative, number (%) | “5,500 (29)” |

Source: [Senkomago et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6705893/)

<a id="topic-4.2.3-11"></a>

### HPV status and PD-L1 expression in the first-line pembrolizumab trial population

> “Twenty-two percent of patients’ tumors were HPV-positive, 23% had PD-L1 TPS ≥50%, and 95% had Stage IV disease”
> “Eighty-five percent of patients’ tumors had PD-L1 expression of CPS ≥1 and 43% had CPS ≥20.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

> “Of 882 participants enrolled, 128 had PD-L1 CPS < 1 and 373 had CPS 1-19.”

Source: [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

<a id="topic-4.2.3-12"></a>

### PD-L1 testing before first-line therapy in United States practice

> “Of 2,207 patients, 32.7 % received PD-L1 testing before 1L therapy initiation, 17.4 % after 1L therapy initiation, and 50.0 % were never tested.”

Source: [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/)

<a id="topic-4.2.3-13"></a>

### First-line treatment mix and receipt of later lines in United States practice

> “1410 patients (54.7%) were treated with anti-PD1 monotherapy, 577 (22.4%) with combination anti-PD1 plus chemotherapy, and 590 (22.9%) with cetuximab plus chemotherapy in the front-line setting for recurrent or metastatic disease.”
> “Out of 2577 patients, 1128 patients (43.8%) were reported to have received second line treatment”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12099209/)

<a id="topic-4.2.3-14"></a>

### Company estimate of newly diagnosed HPV-negative patients in the United States

> “HPV-negative patients newly diagnosed each year in the US, EU5 and Japan”
> “of those patients in the US alone”
> “Tessellon patient flow modeling; SEER; country-specific registries; literature review.”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
